Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT ID: NCT02796937

Last Updated: 2025-10-08

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: PHASE3
• Total Enrollment: 290 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2029-02-28

Brief Summary

This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60 mg/kg/week in subjects with alpha1-antitrypsin deficiency (AATD).

Detailed Description

This is a 2-year open-label extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha-1 MP 60 mg/kg/week in subjects with AATD.

The study consists of a Screening Visit (the same visit as the End-of-Study Visit in the GTi1201 study for subjects who complete the GTi1201 study or is the same visit as the Early Discontinuation Visit for subjects meeting the early withdrawal criterion for forced expiratory volume in 1 second [FEV1] decline), a treatment period of 104 weeks (beginning immediately after screening [on the same day as the Screening Visit] but no sooner than 1 week after the last infusion of investigational product in the GTi1201 study), and an End-of-Study Visit.

Subjects meeting the entrance criteria of the extension study will begin receiving weekly intravenous (IV) infusions of Alpha-1 MP 60 mg/kg on the day of screening and will continue to receive weekly infusions for a total of 104 infusions.

Safety assessments will include adverse events, concomitant medications, complete physical examination (excluding breast and genitourinary examination), hematology, chemistry, urine cotinine, and pregnancy test. Efficacy assessments will include whole lung computed tomography density, quality-of-life assessment, carbon monoxide diffusing capacity, and pulmonary function tests. The occurrence of chronic obstructive pulmonary exacerbations, will also be evaluated as a safety and as an efficacy measurement.

Conditions

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Alpha-1 MP

Alpha-1 MP 60 mg/kg/week for up to 104 weeks

Group Type: EXPERIMENTAL

Alpha-1 MP

Intervention Type: BIOLOGICAL

Alpha-1 MP 60 mg/kg/week for up to 104 weeks

Interventions

Alpha-1 MP

Alpha-1 MP 60 mg/kg/week for up to 104 weeks

Intervention Type: BIOLOGICAL

Other Intervention Names

Prolastin-C

Eligibility Criteria

Inclusion Criteria

• Has completed participation in Study GTi1201 (ie, completed Week 156 and Week 160/End-of-Study Visit) OR has experienced a decline in FEV1 at the annualized rate of ≥134.4 mL/year at or after the Week 104 Visit in GTi1201.
• Is willing and able to provide informed consent

Exclusion Criteria

• Is unable to physically or mentally undergo a CT scan (eg, unable to fit inside the CT scanner, claustrophobic).
• Has severe concomitant disease including, but not limited to, congestive heart failure and liver cirrhosis.
• Has primary and/or secondary (metastatic disease) pulmonary malignancy or other current malignancy with <1 year predicted overall survival.
• Has a metal object (newly received since starting GTi1201) that might interfere with chest CT quality and quantification. Metal objects include, but are not limited to, cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile, metal weapon fragments, or metal shoulder prosthesis.
• Is a female who is pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable, or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; condom or occlusive cap with spermicidal foam/gel/film/cream/suppository; male sterilization; or abstinence) throughout the study.
• Has clinical signs and symptoms of viral infection requiring virus safety testing at the Week 160/End-of-Study Visit or Early Discontinuation Visit in Study GTi1201, and the virus safety test results are indicative of acute or chronic infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or parvovirus B19 (B19V). Note: If the virus safety test results are indicative of acute or chronic infection with HAV, HBV, HCV, HIV, or B19V, the subject will be considered a screen failure and must be withdrawn from the study.
• Has current evidence of smoking, which includes electronic/vapor cigarettes, or has a positive urine cotinine test at the Week 160/End-of- Study Visit in Study GTi1201 that is due to smoking.
• Has current evidence of chronic alcoholism or illicit drug abuse (addiction).
• Is currently participating in another investigational product (IP) study.
• Has a history of anaphylaxis or severe systemic response to any plasma- derived alpha1-PI preparation or other blood product(s).
• In the opinion of the investigator, is likely to have compliance problems with the protocol and the procedures of the protocol.
• Has any medical condition that the investigator feels might confound the results of the study or pose an additional risk to the subject during study participation.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 72 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Grifols Therapeutics LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

University Of Miami Hospital, Doctors Office West Building

Miami, Florida, United States

Accellacare

Wilmington, North Carolina, United States

Oregon Health & Science University

Portland, Oregon, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Texas Health Center at Tyler

Tyler, Texas, United States

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Royal Adelaide Hospital

Adelaide, , Australia

The Prince Charles Hospital

Chermside, , Australia

St Vincent's Hospital Melbourne

Fitzroy, , Australia

Institute for Respiratory Health Inc

Nedlands, , Australia

Queen Elizabeth II Health Sciences Centre

Halifax, , Canada

Inspiration Research Limited

Toronto, , Canada

Arhus Universitetshospital

Arhus C, , Denmark

Gentofte Hospital

Hellerup, , Denmark

North Estonia Medical Centre Foundation

Tallinn, , Estonia

Turun yliopistollinen keskussairaala

Turku, , Finland

CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel

Bron, Rhone, France

NZ Respiratory and Sleep Institute

Auckland, , New Zealand

Christchurch Hospital NZ

Christchurch, , New Zealand

Waikato Hospital

Hamilton, , New Zealand

SPZOZ Szpital Uniwersytecki w Krakowie

Krakow, , Poland

Instytut Gruzlicy i Chorob Pluc w Warszawie

Warsaw, , Poland

SBEI HPE Altai State Medical University of MoH and SD

Barnaul, , Russia

Sahlgrenska Sjukhuset

Gothenburg, , Sweden

Skånes Universitetssjukhus, Malmö

Malmo, , Sweden

Karolinska Trial Allicance, KTA Prim

Stockholm, , Sweden

Countries

United States; Australia; Canada; Denmark; Estonia; Finland; France; New Zealand; Poland; Russia; Sweden

Other Identifiers

GTi1201-OLE

Identifier Type: -

Identifier Source: org_study_id